Hikma V. Amarin: The Amici Speak – Part II

Why It Matters

A decision favoring Amarin could tighten liability for generic manufacturers, reshaping patent enforcement and affecting the balance between affordable drugs and R&D incentives.

Key Takeaways

• Amici claim Hikma’s inaction makes induced infringement plausible.
• Section VIII skinny‑label carve‑out should not shield liability.
• Court’s ruling could reshape patent enforcement for generic drugs.
• Maintaining Twombly/Iqbal standards preserves flexible pleading in IP cases.

Pulse Analysis

The *Hikma v. Amarin* dispute centers on a generic drug that carries a "skinny label"—a narrow indication that avoids a patented use while the drug’s broader, off‑label applications remain unregulated. Hikma’s generic version is marketed for a cardiovascular indication, yet evidence suggests 75% of prescriptions were for the patented use. Amarin argues that Hikma’s knowledge of this pattern, combined with its failure to warn wholesalers or physicians, satisfies the intent‑based test for induced infringement under 35 U.S.C. § 271(b). The case thus pits the statutory safe harbor of Section VIII against the doctrine that a defendant can be liable for encouraging downstream infringement.

Amicus briefs filed by industry giants such as AbbVie, BMS, and the American Intellectual Property Law Association reinforce a broader view of inducement: knowledge of pervasive infringement and a lack of mitigation can establish liability, even without explicit encouragement. They cite precedent from *Grokster*, *Global‑Tech*, and recent decisions like *Twitter v. Taamneh* to argue that the totality‑of‑circumstances test remains robust. Moreover, the briefs caution that expanding the skinny‑label exemption would create a “free pass” for generics, undermining the Hatch‑Waxman balance that rewards innovators while eventually allowing cheaper competition.

The stakes extend beyond a single patent dispute. If the Court narrows the safe harbor, generic manufacturers may need to implement more rigorous monitoring and labeling practices, potentially raising costs and slowing market entry. Conversely, preserving the current carve‑out could preserve low‑cost access but risk diminishing incentives for developing new drug indications. The decision will also signal how courts will apply Twombly/Iqbal pleading standards in complex IP cases, influencing the strategic calculus of both brand‑name and generic firms in future litigation.